IRX4204: Clinical Trials

3 trials of IRX4204, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 suspended, 1 terminated. 2 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 12Completed 1, Terminated 1
Phase 21Suspended 1

Follow IRX4204: new trials by email Literature Review of IRX4204 trials Research Report on IRX4204

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluation of Safety and Efficacy of IRX4204 in Mild to Moderate Plaque Psoriasis
IRX4204, Placebo - Psoriasis, Plaque Type Psorisis
Phase 2SuspendedIo Therapeutics202027-03-012026-11-12
Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC
IRX4204, erlotinib - Lung Cancer, Nonsmall Cell
Phase 1TerminatedIo Therapeutics122016-12-072025-05-14
Study of IRX4204 for Treatment of Early Parkinson's Disease
IRX4204 - Parkinson's Disease
Phase 1CompletedIo Therapeutics152014-08-012015-05-12

Conditions studied

Carcinoma, Non-Small-Cell Lung (1)  ·  Parkinson Disease (1)  ·  Plaque, Amyloid (1)  ·  Psoriasis (1)

Sponsors

Io Therapeutics (3)

Countries

United States (3)

Top investigators

Ken Marek, MD (1)  ·  Martin E Sanders, MD (1)